Press Releases Pliant Therapeutics, Inc.

Equities

PLRX

US7291391057

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-01 pm EDT			5-day change	1st Jan Change
12.66 ^USD	+7.11%		+6.39%	-30.09%

Mar. 12	Pliant Therapeutics, Inc. Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis	CI
Mar. 05	RBC Lifts Price Target on Pliant Therapeutics to $54 From $50, Says Bexotegrast Could Have Multi-Billion-Dollar Revenue Opportunity; Outperform, Speculative Risk Kept	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pliant Therapeutics to Participate in Upcoming Investor Events	May. 01	GL
Pliant Therapeutics to Participate in Upcoming Investor Events	May. 01	AQ
Pliant Therapeutics to Participate in Upcoming Investor Events	Apr. 02	GL
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference	Mar. 27	GL
Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors	Mar. 13	AQ
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis	Mar. 12	GL
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis	Mar. 12	AQ
Pliant Therapeutics : March 2024 Corporate Presentation	Feb. 28	PU
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results	Feb. 27	GL
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results	Feb. 27	AQ
Pliant Therapeutics to Participate in Upcoming Investor Conferences	Feb. 26	GL
Pliant Therapeutics to Participate in Upcoming Investor Conferences	Feb. 26	AQ
Pliant Therapeutics to Participate in Upcoming Investor Events	Feb. 07	GL
Pliant Therapeutics to Participate in Upcoming Investor Events	Feb. 07	AQ
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis	Feb. 04	AQ
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis	Feb. 04	GL
Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 03	GL
Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis	Nov. 13	GL
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results	Nov. 09	GL
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results	Nov. 09	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Pliant Therapeutics, Inc.

Equities

PLRX

US7291391057

Press Releases

Filters